Search hospitals
>
New York
>
New York
Memorial Sloan Kettering Cancer Center
Claim this profile
New York, New York 10065
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
4169 reported clinical trials
427 medical researchers
Summary
Memorial Sloan Kettering Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Memorial Sloan Kettering Cancer Center is involved with conducting 4,169 clinical trials across 1,801 conditions. There are 427 research doctors associated with this hospital, such as Christopher J. Forlenza, Alan L Ho, MD, PhD, Andrea Cercek, MD, and Thomas Kaley, MD.
Area of expertise
Cancer
Memorial Sloan Kettering Cancer Center has run 550 trials for Cancer. Some of their research focus areas include:
Breast Cancer
Memorial Sloan Kettering Cancer Center has run 507 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Christopher J. Forlenza
Memorial Sloan Kettering Cancer Center
8 years of reported clinical research
Alan L Ho, MD, PhD
Memorial Sloan Kettering Cancer Center
1 year of reported clinical research
Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center
3 years of reported clinical research
Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center
7 years of reported clinical research
Clinical Trials running at Memorial Sloan Kettering Cancer Center
Lung Cancer
Breast Cancer
Skin Cancer
Cancer
Brain Tumor
Ovarian Cancer
Bladder Cancer
Cervical Cancer
Testicular cancer
Multiple Myeloma
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting
2 awards
Phase 3
3 criteria
Sotorasib Combo vs Pembrolizumab Combo
for Advanced Lung Cancer
This trial is testing two different drug combinations with chemotherapy to see which helps cancer patients live longer without their disease getting worse. One combination includes sotorasib, which targets cancer mutations, and the other includes pembrolizumab, which helps the immune system fight cancer. Pembrolizumab has been shown to improve overall survival in various cancers when combined with chemotherapy.
Recruiting
2 awards
Phase 3
3 criteria
Neladalkib
for Non-Small Cell Lung Cancer
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Recruiting
2 awards
Phase 3
4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Memorial Sloan Kettering Cancer Center?
Memorial Sloan Kettering Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Memorial Sloan Kettering Cancer Center is involved with conducting 4,169 clinical trials across 1,801 conditions. There are 427 research doctors associated with this hospital, such as Christopher J. Forlenza, Alan L Ho, MD, PhD, Andrea Cercek, MD, and Thomas Kaley, MD.
Where is Memorial Sloan Kettering Cancer Center located?
Memorial Sloan Kettering Cancer Center is situated at 1275 York Avenue, New York, NY, nestled between 67th and 68th streets. For the main entrance, head south on York Avenue and make a right turn onto East 66th Street. The parking garage is conveniently located a quarter block from the corner, on the right side of 66th Street.
Who should I call to ask about financial aid or insurance network?
Memorial Sloan Kettering Cancer Center (MSK) offers comprehensive support for patients, including: - **Insurance Assistance**: For queries, contact 800-525-2225. - **Financial Assistance Program (FAP)**: Helps manage treatment costs based on income and assets. Apply by calling 646-227-3378. - **Prescription Assistance**: Aids patients with high medication co-pays. - **Social Worker Support**: Offers emotional support and practical assistance, including transportation and financial issues.
What insurance does Memorial Sloan Kettering Cancer Center accept?
Memorial Sloan Kettering Cancer Center (MSK) accepts various insurance plans, including Medicare and Medicaid. Patients are responsible for co-insurance, deductible costs for Medicare, and co-payments for Medicaid. MSK has relationships with many insurance providers, including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare, among others. For specific plan participation and financial assistance options, please contact MSK directly. For insurance inquiries, call 646-497-9176; for billing questions, call 646-227-3378, Monday through Friday.
What awards or recognition has Memorial Sloan Kettering Cancer Center received?
Memorial Sloan Kettering Cancer Center (MSK) is renowned for its groundbreaking research and exceptional care, leading over 900 clinical trials aimed at enhancing treatment for adult and pediatric cancers. From 1980 to 2015, the US Food and Drug Administration approved ten drugs developed by MSK, showcasing an unmatched success rate among cancer centers. Additionally, MSK scientists have earned national and international accolades for their pioneering contributions to science and medicine.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.